HITK: Generic Pharma

The large volume breakout area held as support, the gap from 12/9/2009 will be the stop loss. 

Hi-Tech Pharmacal is another cutting-edge health care company. While big pharma is spending billions on research for the next blockbuster drug, HITK is finding innovative ways to challenge patents and deliver the same prescriptions to consumers at a much cheaper price.Hi-Tech's latest earnings rose 566.7% to $7.4 million, or 60 cents per share, compared with $1.1 million, or 9 cents per share, in the same quarter a year ago. In the past month, the analyst community has revised its earnings estimate 29.6% higher in anticipation of another strong report in early 2010. (TheStreet.com)